Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer

Key Points

• This research aims to compare the safety and effectiveness of low-molecular-weight heparin versus warfarin in preventing venous thromboembolism in cancer patients.
• Comparison of bleeding rates and treatment outcomes between low-molecular-weight heparin and warfarin
• Analysis conducted in a population of cancer patients with venous thromboembolism
• Warfarin treatment was linked to a high bleeding rate in patients with cancer and venous thromboembolism.
• Low-molecular-weight heparin showed effectiveness similar to that of oral anticoagulants, potentially indicating safer treatment options.